-
From animal models to gut-on-chip: the challenging journey to capture inter-individual variability in chronic digestive disorders Gut Microbes (IF 12.2) Pub Date : 2024-03-27 Aicha Kriaa, Vincent Mariaule, Charlotte De Rudder, Amin Jablaoui, Harry Sokol, Paul Wilmes, Emmanuelle Maguin, Moez Rhimi
Chronic digestive disorders are of increasing incidence worldwide with expensive treatments and no available cure. Available therapeutic schemes mainly rely on symptom relief, with large degrees of...
-
Oral pathobiont Klebsiella chaperon usher pili provide site-specific adaptation for the inflamed gut mucosa Gut Microbes (IF 12.2) Pub Date : 2024-03-28 Yijie Guo, Sho Kitamoto, Gustavo Caballero-Flores, Yeji Kim, Daisuke Watanabe, Kohei Sugihara, Gabriel Núñez, Christopher J. Alteri, Naohiro Inohara, Nobuhiko Kamada
The ectopic gut colonization by orally derived pathobionts has been implicated in the pathogenesis of various gastrointestinal diseases, including inflammatory bowel disease (IBD). For example, gut...
-
Transplant of microbiota from Crohn’s disease patients to germ-free mice results in colitis Gut Microbes (IF 12.2) Pub Date : 2024-03-27 Irshad Ali Sheikh, Jared Bianchi-Smak, Daniel Laubitz, Gabriele Schiro, Monica T. Midura-Kiela, David G. Besselsen, Gayatri Vedantam, Sara Jarmakiewicz, Rafał Filip, Fayez K. Ghishan, Nan Gao, Pawel R. Kiela
Although the role of the intestinal microbiota in the pathogenesis of inflammatory bowel disease (IBD) is beyond debate, attempts to verify the causative role of IBD-associated dysbiosis have been ...
-
Intestinal microbiota modulates neuroinflammatory response and brain injury after neonatal hypoxia-ischemia Gut Microbes (IF 12.2) Pub Date : 2024-03-27 Alexander Drobyshevsky, Sylvia Synowiec, Ivan Goussakov, Rafael Fabres, Jing Lu, Michael Caplan
Premature infants lack a normal intestinal microbial community and also at risk of perinatal hypoxic-ischemic (HI) brain injury, which is considered to be one of the major factors for motor, sensor...
-
Ferritin—a promising biomarker in MASLD Gut (IF 24.5) Pub Date : 2024-03-27 Heinz Zoller, Herbert Tilg
Human ferritins are expressed in essentially all cells of the human body. From an evolutionary perspective, human ferritins are part of a diverse ferritin-like superfamily—the ‘rubrerythins’, that include plant ferritins and bacterioferritins, where they cover a wide range of biological functions.1 Although best known as a 24-meric intracellular iron storage protein, ferritin is also present in the
-
Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway Gut Microbes (IF 12.2) Pub Date : 2024-03-27 Ni Wang, Lu Zhang, Xiao-Xu Leng, Yi-Le Xie, Zi-Ran Kang, Li-Cong Zhao, Lin-Hong Song, Cheng-Bei Zhou, Jing-Yuan Fang
Chemotherapy resistance is one of the main reasons for the poor prognosis of colorectal cancer (CRC). Moreover, dysbiosis of gut bacteria was found to be a specific environmental risk factor. In th...
-
Is acute necrotising pancreatitis a chronic disease? Gut (IF 24.5) Pub Date : 2024-03-26 Deepak Gunjan, Soumya Jagannath Mahapatra, Pramod Kumar Garg
Acute pancreatitis (AP) is a common disease with an annual incidence of 34 (23–49) per 100 000 population.1 Patients with acute interstitial pancreatitis have a shorter self-limiting disease course while acute necrotising pancreatitis (ANP) is a much more severe disease with major local and systemic complications mandating prolonged hospitalisation.2 Among the local complications, acute necrotic fluid
-
Re-evaluating early-onset OSCC in Africa: findings of minimal cumulative incidence Gut (IF 24.5) Pub Date : 2024-03-26 Mohamed Noureldin, Joel H Rubenstein, Brooke Kenney, Akbar K Waljee
We read Arnold et al ’s article1 with interest and wanted to extend this work to Africa. A high incidence of oesophageal squamous cell carcinoma (OSCC) has been reported in African countries from Kenya to South Africa2 where early-onset (age <45 years) OSCC accounts for 30% of cases in the region. As such, we examined the cumulative lifetime and age-specific incidences of OSCC in Africa. We identified
-
Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-27 Timothy McAuliffe, Joseph C. Anderson, Robin J. Larson, Douglas J. Robertson
SummaryBackgroundThe faecal immunochemical test (FIT) is an inexpensive and convenient modality to screen for colorectal cancer. However, its one‐time sensitivity for detecting colorectal cancer and cancer precursors is limited. There is growing interest in using the non‐haemoglobin contents of FIT residual buffer to enhance colonic neoplasia detection.AimTo establish from the literature a framework
-
The epidemiology and management of Clostridioides difficile infection—A clinical update Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-27 Lindsay M. Clarke, Jessica R. Allegretti
SummaryBackgroundClostridioides difficile is the most common cause of healthcare‐associated infection, and severe cases can result in significant complications. While anti‐microbial therapy is central to infection management, adjunctive therapies may be utilised as preventative strategies.AimThis article aims to review updates in the epidemiology, diagnosis, and management, including treatment and
-
Indole-3-acetic acid alleviates DSS-induced colitis by promoting the production of R-equol from Bifidobacterium pseudolongum Gut Microbes (IF 12.2) Pub Date : 2024-03-25 Miaomiao Li, Xue Han, Lijun Sun, Xinjuan Liu, Weizhen Zhang, Jianyu Hao
Inflammatory bowel disease (IBD) is characterized by immune-mediated, chronic inflammation of the intestinal tract. The occurrence of IBD is driven by the complex interactions of multiple factors. ...
-
Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers Gut (IF 24.5) Pub Date : 2024-03-25 Jonel Trebicka, Ruben Hernaez, Debbie Lindsay Shawcross, Alexander L Gerbes
The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation
-
Tackling sorbitol intolerance Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-25 Maria Papatriantafyllou
Sorbitol, a poorly absorbable sweetener, is catabolized by gut microbiota, mainly Clostridia. Lee et al. now elucidate the pathophysiology of sorbitol intolerance and highlight a role for Clostridia and butyrate, a short-chain fatty acid metabolite. Stable engraftment of Escherichia coli strain Nissle 1917, a probiotic that catabolizes sorbitol, restored caecal SDH activity in mice and protected them
-
Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 Jian Wang, Tao Fan, Shaoqiu Zhang, Chao Wu, Rui Huang
LINKED CONTENTThis article is linked to Hong et al papers. To view these articles, visit https://doi.org/10.1111/apt.17819 and https://doi.org/10.1111/apt.17937
-
Letter: Thioguanine, an underutilised option in inflammatory bowel disease? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 John D. Chetwood, Sudarshan Paramsothy, Rupert W. Leong
LINKED CONTENTThis article is linked to Vasudevan et al papers. To view these articles, visit https://doi.org/10.1111/apt.17831 and https://doi.org/10.1111/apt.17957
-
Editorial: Muscles at the expense of liver injury. Is it worth it? Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 C. Stephens
LINKED CONTENTThis article is linked to Nash et al paper. To view this article, visit https://doi.org/10.1111/apt.17906
-
Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 Hyeyeon Hong, Jonggi Choi
LINKED CONTENTThis article is linked to Hong et al papers. To view these articles, visit https://doi.org/10.1111/apt.17819 and https://doi.org/10.1111/apt.17922
-
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 Matthias Lenfant, Bram Verstockt, João Sabino, Séverine Vermeire, Marc Ferrante
LINKED CONTENTThis article is linked to Lenfant et al papers. To view these articles, visit https://doi.org/10.1111/apt.17753 and https://doi.org/10.1111/apt.17912
-
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 Kunio Asonuma, Shintaro Sagami, Taku Kobayashi
LINKED CONTENTThis article is linked to Lenfant et al papers. To view these articles, visit https://doi.org/10.1111/apt.17753 and https://doi.org/10.1111/apt.17935
-
Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 Abhinav Vasudevan, Danny Con, Daniel R. van Langenberg
LINKED CONTENTThis article is linked to Vasudevan et al papers. To view these articles, visit https://doi.org/10.1111/apt.17831 and https://doi.org/10.1111/apt.17920
-
-
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-25 Danielle Adebayo, Florence Wong
-
Seladelpar in primary biliary cholangitis Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-22 Eleni Kotsiliti
In a phase III, double-blind, placebo-controlled trial, 193 patients with primary biliary cholangitis and an inadequate response to or a history of unacceptable side effects with ursodeoxycholic acid were randomly assigned in a 2:1 ratio to receive daily 10 mg oral seladelpar (a PPARδ agonist) or placebo. The primary endpoint was set at month 12 as a biochemical response defined as an alkaline phosphatase
-
Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD) Gut Microbes (IF 12.2) Pub Date : 2024-03-21 Raquel Benedé-Ubieto, Francisco Javier Cubero, Yulia A. Nevzorova
Obesity, insulin resistance (IR), and the gut microbiome intricately interplay in Metabolic-associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD)...
-
HCC genomic landscape in Chinese individuals Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-22 Eleni Kotsiliti
Researchers from the Chinese Liver Cancer Atlas project performed deep whole-genome sequencing of hepatocellular carcinoma (HCC) tumours from 494 Chinese individuals (86.4% men and 13.6% women) who received no preoperative anti-cancer treatment. According to epidemiological data, 94.5% of the enrolled patients had hepatitis B, 2.6% had hepatitis C, 26.7% drank alcohol and 36.8% smoked. The researchers
-
Bacteriophages and host inflammation in IBD Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-22 Eleni Kotsiliti
Researchers analysed metagenomic data from 1,618 patients with inflammatory bowel disease (IBD) and 791 healthy individuals as controls and identified invertible DNA orientations in Bacteroidales genomes. Of those 311 invertible regions, 147 were markedly different in terms of orientation in patients with IBD. The inverted regions included, among others, the anti-inflammatory PSA promoter of Bacteroides
-
Biomarker shows no clinical use in guiding treatment for Crohn’s disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-22 Eleni Kotsiliti
Between 29 December 2017 and 5 January 2022, in a multicentre, open-label, biomarker-stratified, interventional clinical trial (PROFILE), 386 adult patients with newly diagnosed active Crohn’s disease were randomly assigned to two groups: top-down (early combined immunosuppression with infliximab (a TNF monoclonal antibody) and an immunomodulator) or accelerated step-up (conventional) treatment. The
-
Cholecystectomy following EUS-guided gallbladder drainage in patients with acute cholecystitis at high surgical risk: friend or foe? Gut (IF 24.5) Pub Date : 2024-03-22 Alberto Larghi, Roy L J van Wanrooij, Michiel Bronswijk, Giuseppe Vanella, Rastislav Kunda, Manuel Pérez-Miranda, Jeanin E Van-Hooft, Marc A Barthet, Paolo Giorgio Arcidiacono, Schalk Willem Van der Merwe
We read with great interest the paper by Bang et al ,1 reporting their single-centre retrospective experience in 25 patients with acute cholecystitis, who were deemed at increased surgical risk and treated by EUS-guided gallbladder drainage (EUS-GBD) using LAMS. Three patients underwent surgery because of persistent biliary-type symptoms, but the presence of LAMS precluded successful laparoscopic cholecystectomy
-
Selective decontamination of the digestive tract in critically ill children: fighting fire with fire or burning down the house? Gut (IF 24.5) Pub Date : 2024-03-22 Debby Bogaert, Willem van Schaik
The microbial ecosystem of the human gut (‘the gut microbiome’) plays an important role in human health through a variety of mechanisms, including the degradation of complex carbohydrates, the production of vitamins and other beneficial compounds and by providing a barrier to invading pathogens.1 The gut can also be the source of pathobionts, including the Gram-negatives Escherichia coli , Klebsiella
-
Unusual cause of rectal bleeding in a patient with schizophrenia Gut (IF 24.5) Pub Date : 2024-03-22 Rebecca K Grant, Charu Chopra, Pujit Gandhi, Natarajan Manimaran, Jonathan T Serhan, Kate L Struthers, William M Brindle
A gentleman in his early 40s with a background of schizophrenia on clozapine presented with a 2-month history of rectal bleeding, diarrhoea, weight loss, a microcytic anaemia and a quantitative faecal immunochemical test (qFIT) result >400 µg Hb/g. Colonoscopy demonstrated multiple large polypoid lesions in the rectum and in the sigmoid colon; the sigmoid was unable to be passed by the colonoscope
-
Head of pancreas mass with biliary obstruction: an unusual cause Gut (IF 24.5) Pub Date : 2024-03-22 Raymond Hayler, Colin Tuft, Oliver Fisher
A woman in her 70s presented to an Australian centre with right upper quadrant pain, fevers and weight loss. She was born in Greece, having lived in Australia for 50 years. Significant background included chronic lymphocytic leukaemia (CLL), treated with venetoclax and rituximab. Her white cell count was 3.20×109/L with normal liver function tests, bilirubin of 6 µmol/L and C reactive protein of 15
-
mNFE: microbiome network flow entropy for detecting pre-disease states of type 1 diabetes Gut Microbes (IF 12.2) Pub Date : 2024-03-21 Rong Gao, Peiluan Li, Yueqiong Ni, Xueqing Peng, Jing Ren, Luonan Chen
In the development of Type 1 diabetes (T1D), there are critical states just before drastic changes, and identifying these pre-disease states may predict T1D or provide crucial early-warning signals...
-
Using a human colonoid-derived monolayer to study bacteriophage translocation Gut Microbes (IF 12.2) Pub Date : 2024-03-22 Huu Thanh Le, Alicia Fajardo Lubian, Bethany Bowring, David van der Poorten, Jonathan Iredell, Jacob George, Carola Venturini, Golo Ahlenstiel, Scott Read
Bacteriophages (phages) are estimated to be the most abundant microorganisms on Earth. Their presence in human blood suggests that they can translocate from non-sterile sites such as the gastrointe...
-
Review article: Upper gastrointestinal bleeding – review of current evidence and implications for management Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-22 Dennis L. Shung, Loren Laine
-
Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-22 Rohit Loomba, Ginger Clark, Jeff Teckman, Veeral Ajmera, Cynthia Behling, Mark Brantly, David Brenner, Jeanine D'Armiento, Michael W. Fried, Janani S. Iyer, Mattias Mandorfer, Don C. Rockey, Monica Tincopa, Raj Vuppalanchi, Zobair Younossi, Aleksander Krag, Alice M. Turner, Pavel Strnad
-
Featured Cover Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-20 Xiao Cheng, Yujun Tang, Qinjun He, Jiankang Song, Kunyuan Wang, Hui Li, Jing Huang, Weibin Wang, Junying Li, Haiyu Wang, Minghan Tu, Jinzhang Chen, Guosheng Yuan, Shuai Kang, Hongyan Liu, Xiaoyong Zhang, Wenfan Luo, Yali Ji, Xiaoqin Lan, Ling Zhou, Qintao Lai, Xiaoqin Luo, Qiaoping Wu, Damei Zhou, Yingqi Tan, Jinjun Chen, Xiaofeng Zhang
-
CobB-mediated deacetylation of the chaperone CesA regulates Escherichia coli O157:H7 virulence Gut Microbes (IF 12.2) Pub Date : 2024-03-19 Linxing Li, Bin Yang, Jing Wang, Yi Wei, Binbin Xiang, Yutao Liu, Pan Wu, Wanwu Li, Yanling Wang, Xinyu Zhao, Jingliang Qin, Miaomiao Liu, Ruiying Liu, Guozhen Ma, Tian Fu, Min Wang, Bin Liu
Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is a common food-borne pathogen that can cause acute diseases. Lysine acetylation is a post-translational modification (PTM) that occurs in various...
-
Smoking-related Lactobacillus and immune cell infiltration in colorectal cancer: evidence from a population-based study Gut (IF 24.5) Pub Date : 2024-03-18 Silu Chen, Junyi Xin, Dongying Gu, Huiqin Li, Rui Zheng, Shuwei Li, Zhengdong Zhang, Mulong Du, Meilin Wang
Recently, we were intrigued by a recent study by Fong and colleagues,1 in which they found that Lactobacillus gallinarum could reduce regulatory T-cell (Treg) infiltration and enhance CD8+ T-cell effector function, thus improving anti-PD1 efficacy in patients with colorectal cancer, which was confirmed in mouse models. Interestingly, Lactobacillus was observed to be related to smoke exposure, with
-
Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity? Gut (IF 24.5) Pub Date : 2024-03-18 Samy Suissa, Ruben Hernaez
Chronic liver diseases are prevalent, particularly among patients with type 2 diabetes, who have a higher incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) and are subject to other liver diseases.1 With no pharmacotherapy for these liver conditions, recent attention was given to glucagon-like peptide-1 receptor agonists (GLP1a) for their effectiveness in treating type 2
-
New entity of adult ultra-short coeliac disease: the first international cohort and case–control study Gut (IF 24.5) Pub Date : 2024-03-18 Suneil A Raju, Emily A Greenaway, Annalisa Schiepatti, Giovanni Arpa, Nicoletta Vecchione, Chao LA Jian, Charlotte Grobler, Margherita Maregatti, Olivia Green, Freya J Bowker-Howell, Mohamed G Shiha, Hugo A Penny, Simon S Cross, Carolina Ciacci, Kamran Rostami, Shokoufeh Ahmadipour, Afshin Moradi, Mohammad Rostami-Nejad, Federico Biagi, Umberto Volta, Michelangelo Fiorentino, Benjamin Lebwohl, Peter
Background Ultra-short coeliac disease (USCD) is defined as villous atrophy only present in the duodenal bulb (D1) with concurrent positive coeliac serology. We present the first, multicentre, international study of patients with USCD. Methods Patients with USCD were identified from 10 tertiary hospitals (6 from Europe, 2 from Asia, 1 from North America and 1 from Australasia) and compared with age-matched
-
Local ablation in pancreatic cancer: some answers and more questions Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-19 Zachary T Berman, Rebekah R White
-
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-03-19 Florentine E F Timmer MD, Bart Geboers MD, Alette H Ruarus MD, Laurien G P H Vroomen MD, Evelien A C Schouten MSc, Susan van der Lei MD, Danielle J W Vos MD, Madelon Dijkstra MD, Hannah H Schulz MD, Joyce Bakker BSc, Bente A T van den Bemd MD, Petrousjka M van den Tol MD, Robbert S Puijk MD, Birgit I Lissenberg-Witte PhD, Prof Tanja D de Gruijl PhD, Jan J J de Vries MD, Frank J Lagerwaard MD, Hester
Pancreatic ductal adenocarcinoma is an aggressive disease with a dismal prognosis. Stage III locally advanced pancreatic cancer is considered unresectable and current palliative chemotherapy regimens only modestly improve survival. Guidelines suggest chemoradiation or stereotactic ablative body radiotherapy (SABR) could be beneficial in certain circumstances. Other local treatments such as irreversible
-
Relative Efficacies of Interventions to Improve the Quality of Screening-related Colonoscopy: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials Gastroenterology (IF 29.4) Pub Date : 2024-03-19 Rishad Khan MD, Yibing Ruan PhD MPH, Yuhong Yuan MD PhD, Kareem Khalaf MD, Nasruddin S. Sabrie BSc, Nikko Gimpaya MEd, Michael A. Scaffidi MEd, Rishi Bansal BArtsSc, Marcus Vaska MLIS, Darren R. Brenner PhD, Robert J. Hilsden MD PhD, Steven J. Heitman MD MSc, Grigorios I. Leontiadis MD PhD, Samir C. Grover MD, Nauzer Forbes MD MSc
-
MAF-5 PREDICTS LIVER FIBROSIS RISK AND OUTCOME IN THE GENERAL POPULATION WITH METABOLIC DYSFUNCTION Gastroenterology (IF 29.4) Pub Date : 2024-03-19 Laurens A. van Kleef, Sven M. Francque, Jhon E. Prieto-Ortiz, Milan J. Sonneveld, Carlos B. Sanchez-Luque, Robin G. Prieto-Ortiz, Wilhelmus J. Kwanten, Luisa Vonghia, An Verrijken, Christophe De Block, Zouhir Gadi, Harry L.A. Janssen, Robert J. de Knegt, Willem P. Brouwer
-
Risk of esophageal adenocarcinoma after Helicobacter pylori eradication treatment in a population-based multinational cohort study Gastroenterology (IF 29.4) Pub Date : 2024-03-19 Anna-Klara Wiklund M.D., Giola Santoni Ph.D., Jane Yan M.Sc., Cecilia Radkiewicz M.D. Ph.D., Shaohua Xie M.D. Ph.D., Helgi Birgisson M.D. Ph.D., Eivind Ness-Jensen M.D. Ph.D., My von Euler-Chelpin Ph.D., Joonas H. Kauppila M.D. Ph.D., Jesper Lagergren M.D. Ph.D.
-
Endometriosis is Associated with Higher Healthcare Utilization and Upper Gastrointestinal Symptoms Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-19 Madison Simons PsyD, Michael Cline MD, Ashley Gubbels MD, Cara King MD, Anthony Lembo MD, Stephen Lupe PsyD
-
Algorithm Training and Testing for a Non-Endoscopic Barrett’s Esophagus Detection Test in Prospective Multicenter Cohorts Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-19 Prasad G. Iyer MD MSc, Seth W. Slettedahl MS, Douglas W. Mahoney MS, Maria Giakoumopoulos PhD, Marilyn C. Olson PhD, Martin Krockenberger PhD, William R. Taylor MS, Patrick Foote BS, Calise Berger BS, Cadman Leggett MD, T.T. Wu MD PhD, Eduardo Antpack MD, Gary W. Falk MD MS, Gregory G. Ginsberg MD, Julian A. Abrams MD, Charles J. Lightdale MD, Francisco Ramirez MD, Allon Kahn MD, Herbert Wolfsen MD
-
Severe Fatigue in Inflammatory Bowel Disease: Dopaminergic Therapy with Modanfinil or Vitamin Therapy with Thiamine Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-03-19 Palle Bager, Christian L. Hvas, Jens Frederik Dahlerup
-
Mobile Health technology in pediatric esophagogastroduodenoscopy quality indicators assessment: results from a national program of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition Gastrointest. Endosc. (IF 7.7) Pub Date : 2024-03-19 Lorenzo Norsa, Francesco Morotti, Cecilia Mantegazza, Milena Meroni, Marco Deganello Saccomani, Claudia Banzato, Barbara Parma, Giulia Franchino, Giovanni Di Nardo, Naire Sansotta, Paolo Orizio, Emanuele Dabizzi, Giorgio Raffaele Fava, Andrea Chiaro, Maristella Pellegrino, Fabiola Fornaroli, Antonio Pizzol, Caterina Strisciuglio, Caterina Pacenza, Cosimo Ruggiero, Giusy Russo, Salvatore Oliva
-
Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-19 Carolin V. Schneider, Kai Markus Schneider, Anastasia Raptis, Helen Huang, Christian Trautwein, Rohit Loomba
-
Skeletal muscle mass increases after viral eradication with direct‐acting antivirals in patients with chronic hepatitis C: A longitudinal study Aliment. Pharm. Ther. (IF 7.6) Pub Date : 2024-03-19 Marta Paula Pereira Coelho, Thais Pontello de Vries, Aline Marcos Pires, Milena Pereira Parreira, Érika Ramos de Alvarenga, Rodrigo Dias Cambraia, Rodrigo Ribeiro dos Santos, Juliana Maria Trindade Bezerra, Enrico Antonio Colosimo, Gifone Aguiar Rocha, Luciana Diniz Silva
-
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-03-18 Yasser Fouad, Salma Barakat, Almoutaz Hashim, Hasmik Ghazinyan
Fatty liver disease is one of the most common liver diseases in the Middle East and North Africa region, and globally. Unfortunately, there is a lack of awareness regarding this condition. The nomenclature changes for NAFLD (to MAFLD or MASLD) have gained considerable attention in the hepatology community. Here, we present our point of view on this ongoing change and debate.
-
Efficacy of the traction method in gastric endoscopic submucosal dissection: A randomized controlled trial Gastrointest. Endosc. (IF 7.7) Pub Date : 2024-03-18 Jun Kinoshita MD, Mikitaka Iguchi MD PhD, Takao Maekita MD PhD, Ke Wan PhD, Toshio Shimokawa PhD, Kazuhiro Fukatsu MD PhD, Shinya Taki MD, Fumiaki Kuwashima MD, Masaki Takao MD, Masayuki Kitano MD PhD
To overcome the technical difficulties associated with gastric ESD, a novel traction device that can alter the direction of traction was developed. Here, we compared the efficacy and safety of conventional ESD with that of traction-assisted gastric ESD. Patients with a single gastric epithelial neoplasm were randomized to receive conventional (n=75) or traction-assisted (n=73) gastric ESD. The primary
-
Response Gastrointest. Endosc. (IF 7.7) Pub Date : 2024-03-18 Fady F. Youssef MD MS, Samir Gupta MD MSCS, Gobind Anand MD
-
-
Response Gastrointest. Endosc. (IF 7.7) Pub Date : 2024-03-18 Zaheer Nabi MD DNB, D. Nageshwar Reddy MD DM
-
Oblique fiber preservation in the prevention of GERD after peroral endoscopic myotomy Gastrointest. Endosc. (IF 7.7) Pub Date : 2024-03-18 Yusuke Fujiyoshi MD, Robert Bechara MD, Christopher Teshima MD PhD
-
Harnessing all endoscopic techniques for the management of peptic ulcer bleeding Gastrointest. Endosc. (IF 7.7) Pub Date : 2024-03-18 Maria Manuela Estevinho MD, Teresa Freitas MD, Rolando Pinho MD
-
Different cancers in the same basket: intraductal papillary mucinous neoplasm-derived versus concomitant pancreatic carcinomas Gastrointest. Endosc. (IF 7.7) Pub Date : 2024-03-18 Hiroki Oyama MD PhD, Tsuyoshi Hamada MD MPH PhD, Yousuke Nakai MD PhD, Mitsuhiro Fujishiro MD PhD
-
Propensity score matching is needed to evaluate the clinical success rate of peroral endoscopic myotomy Gastrointest. Endosc. (IF 7.7) Pub Date : 2024-03-18 Yangyang Zhou MD, Qihang Guo MD, Shimeng Zheng MD, Deliang Li MD